Why the study?
Does colchicine improve outcomes and prevent recurrences in patients with pericardial syndromes when added to conventional treatment?
Does colchicine improve outcomes and prevent recurrences in patients with pericardial syndromes when added to conventional treatment?
Colchicine is a safe and effective first-line therapy, added to conventional treatment, for the management of acute and recurrent pericarditis and the prevention of postpericardiotomy syndrome.
Answers are grounded in this paper and cite their sources.
Colchicine merits consideration across pericarditis, CAD, AF, and HF; review extends evidence synthesis but leaves practice change to future trials.
BACKGROUND: Colchicine is an old drug originally employed for the treatment of inflammatory disorders such as acute gout and familiar Mediterranean fever. METHODS: In the past few decades, colchicine has been at the forefront of the pharmacotherapy of several cardiac diseases, including acute and recurrent pericarditis, coronary artery disease, prevention of atrial fibrillation and heart failure. In this review, we have summarized the current evidence based medicine and guidelines recommendations in the specific context of pericardial syndromes. RESULTS: Colchicine has been firstly engaged in the treatment of recurrent pericarditis of viral, idiopathic and autoimmune origin. Shortly thereafter colchicine use has been expanded to the primary prevention of recurrences in patients with a first episode of pericarditis depicting similarly good results. The acquisition of high quality scientific data in the course of time from prospective randomized placebo-controlled trials and metanalyses have established colchicine as first line treatment option in acute and recurrent pericarditis, on top of the conventional treatment. The only concerns related to the use of colchicine are the side effects (mainly gastrointestinal intolerance) which although generally not serious, may account for treatment withdrawal in some cases. CONCLUSION: Colchicine has been established as a first line medication in the treatment of acute (first episode) and recurrent pericarditis on top of the conventional treatment as well as for the prevention of postpericardiotomy syndrome. It depicts a good safety profile with gastrointestinal intolerance being the most common side effect.
No takes yet. Share an insight, caveat, or question.
Lazaros et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: